Skip to main content

Advertisement

SpringerLink
Log in

Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background and aim

Soluble c-erbB-2 oncoprotein has been proven as a useful marker in the management of breast cancer patients, but its value in diagnostics and follow-up of colorectal cancer patients remains controversial. The aim of this study was to evaluate the usefulness of serum c-erbB-2 monitoring in diagnostics and prediction of disease outcome in rectal cancer patients.

Materials and methods

Serum samples from 88 patients with rectal adenocarcinoma before surgery and from 41 healthy controls were tested for the presence of c-erbB-2 oncoprotein by ELISA, and the patients were followed up for at least 5 years after the surgery.

Results

Preoperative serum c-erbB-2 levels were significantly higher in stage IV patients than in healthy controls (P<0.001) and did not show correlation with preoperative CEA levels. Elevated preoperative serum c-erbB-2 levels showed relatively high specificity (88%) and low sensitivity (44%) in the diagnosis of rectal cancer. Elevated preoperative oncoprotein levels were predictive neither for overall survival nor for development of local recurrence/distant metastases.

Conclusion

Although preoperative serum c-erbB-2 levels were significantly higher in rectal cancer patients than in healthy controls, the soluble c-erbB-2 does not seem to be useful in the diagnosis of rectal cancer due to its low sensitivity. Preoperative serum levels of this oncoprotein were predictive neither for overall survival nor for local recurrence/distant metastases in rectal cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Zabrecky JR, Lam T, McKenzie SJ, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 266:1716–1720

    PubMed  CAS  Google Scholar 

  2. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton B, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A (1992) Elevated soluble c-erbB-2 antigen levels in the sera and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436–1443

    PubMed  CAS  Google Scholar 

  3. Narita T, Funahashi H, Satoh Y, Takagi H (1992) C-erbB-2 protein in the sera of breast cancer patients. Breast Cancer Res Treat 24:97–102

    Article  PubMed  CAS  Google Scholar 

  4. Luo JC, Yu MW, Chen CJ, Santella RW, Carney WP, Brandt-Rauf PW (1993) Serum c-erbB-2 oncopeptide in hepatocellular carcinogenesis. Med Sci Res 21:305–307

    CAS  Google Scholar 

  5. Yonemura Y, Nakai Y, Takamura H, Kaji M, Ninomiya i, Tsugawa K, Sugiyama K, Fujimura T, Miyazaki I, Endou Y, Tanaka M, Sasaki T, Hashimoto T (1993) Serum c-erbB-2 protein for the diagnosis of gastric cancer. Int J Oncol 3:325–329

    Google Scholar 

  6. Marx D, fattahi-Meibodi A, Kudelka R, Uebel T, Kuhn W, Meden H (1998) Detection of p100 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma. Anticancer Res 18:2891–2894

    PubMed  CAS  Google Scholar 

  7. Kandl H, Seymour L, Bezwoda WR (1994) Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. BR J Cancer 70:739–742

    PubMed  CAS  Google Scholar 

  8. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A (1995) Elevated serum c-c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129–1135

    PubMed  CAS  Google Scholar 

  9. Classen S, Kopp R, Possinger K, Weidenhagen R, Eiermann W, Wilmanns W (2002) Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumor Biol 23:70–75

    Article  CAS  Google Scholar 

  10. Vogel W, Kath R, Kosmehl H, Olschowsky E, Hoffken K (1996) The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas. J Cancer Res Clin Oncol 122:118–121

    Article  PubMed  CAS  Google Scholar 

  11. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, Ballesta AM (1997) Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumor Biol 18:188–196

    Article  CAS  Google Scholar 

  12. Lukač J, Kovačevi D, Krušlin B, Spaventi R, Ferenči, Belicza M, DeSyo D, Kusi Z (1998) Relationship between natural killer (NK) cell activity and erbB-2 expression in colorectal cancer patients. Period Biol 100:537–539

    Google Scholar 

  13. Chamberlain NL, Ward RL, Hawkins NJ (1999) Clinicopathological significance of erbB-2 expression in colorectal carcinoma. Oncol Rep 6:527–531

    PubMed  CAS  Google Scholar 

  14. Tsigris C, Karayiannakis AJ, Zbar A, Syrigos KN, Baibas N, Diamantis T, Alexiou D (2002) Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer. Cancer Lett 184:215–222

    Article  PubMed  CAS  Google Scholar 

  15. Polychronidis AC, Tsaroucha AK, Anagnostoulis SK, Efstathiou EE, Georgiadis PG, Simopoulos CE (2003) Serum levels of c-erbB-2 correlate with advanced stage and liver metastasis in colorectal cancer. Folia Med (Plovdiv) 45:12–16

    Google Scholar 

  16. Colon and rectum (1997) In: American Joint Committee on Cancer: AJCC cancer staging manual, 5th edn. Lippincott–Raven, Philadelphia, pp 83–90

    Google Scholar 

  17. World Medical Association. Declaration of Helsinki. Available at: http://www.wma.net/e/policy/b3.htm

Download references

Acknowledgment

This work was supported by Research Grant 0134011 administered by the Ministry of Science, Education and Sports, Republic of Croatia.

Author information

Authors and Affiliations

  1. Department of Surgery, Sisters of Charity University Hospital, Vinogradska 29, 10000, Zagreb, Croatia

    Dujo Kovačevi

  2. Department of Oncology and Nuclear Medicine, Sisters of Charity University Hospital, Vinogradska 29, 10000, Zagreb, Croatia

    Zvonko Kusi, Ante Bolanča, Maja Lukač & Josip Lukač

  3. Department of Obstetrics and Gynecology, Sisters of Charity University Hospital, Vinogradska 29, 10000, Zagreb, Croatia

    Goran Grubiši

  4. School of Public Health, Rockefellerova 4, 10000, Zagreb, Croatia

    Zdenko Sonicki

Authors
  1. Dujo Kovačevi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zdenko Sonicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zvonko Kusi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ante Bolanča
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Goran Grubiši
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maja Lukač
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Josip Lukač
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josip Lukač.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kovačevi, D., Sonicki, Z., Kusi, Z. et al. Preoperative serum levels of c-erbB-2 do not seem to be useful in management of patients with rectal cancer. Int J Colorectal Dis 22, 827–831 (2007). https://doi.org/10.1007/s00384-006-0200-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-006-0200-z

Keywords

Search

Navigation